Agennix AG announced that the class action lawsuit brought against its predecessor, GPC Biotech AG, in the United States District Court for the Southern District of New York, is now fully closed.

In March 2009, the Court issued an order dismissing the consolidated class action complaint against GPC Biotech in the action that was commenced in July 2007. Pursuant to that order, the plaintiffs were given the opportunity to file a motion seeking permission of the Court to file an amended consolidated class action complaint. The plaintiffs subsequently filed this motion with the Court and the company opposed the request. On December 29, 2009 the Court issued a decision denying the plaintiff’s request to file an amended complaint and ordered that judgement be entered dismissing the complaint in accordance with the Court’s decision of March 12, 2009, with prejudice. The period to file an appeal to that decision has now expired and the case is fully closed.

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients.